From Tradition to Innovation: The Clinical Edge of Ferric Carboxymaltose in Managing Iron Deficiency Anemia

Abstract

Iron deficiency (ID) and iron deficiency anemia (IDA) are significant global health challenges, accounting for 70% of anemia cases worldwide. IDA stems from factors such as poor iron intake, high physiological demands, chronic blood loss, and malabsorption. Effective management requires accurate diagnosis, addressing the underlying causes, and choosing appropriate treatments, including oral and intravenous (IV) iron supplements. Recent advances in IV iron therapy have introduced Ferric carboxymaltose (FCM), a third-generation IV iron product known for its stability, low risk of immunogenic reactions, and clinical effectiveness. FCM is particularly beneficial in treating ID associated with chronic heart failure, chronic kidney disease, pregnancy-related anemia, and perioperative anemia. Its ability to provide high-dose iron in a single infusion improves patient compliance and reduces healthcare costs. Most existing review articles focus exclusively on either the pharmacological properties or the clinical applications of FCM. This review aims to integrate both perspectives, providing a thorough overview of the pharmacological characteristics and clinical efficacy of FCM. This dual focus will demonstrate the clinical superiority of FCM among available IV iron preparations, positioning FCM as a highly dependable treatment for managing IDA.